Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

15.45 -0.39 (-2.49%)
Streaming Delayed Price Updated: 3:05 PM EDT, May 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.  - TVTX
From Pomerantz LLP
Via GlobeNewswire
Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS
From Travere Therapeutics, Inc.
Via Business Wire
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
Travere Therapeutics to Participate at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via Business Wire
Travere Therapeutics Reports First Quarter 2025 Financial Results
From Travere Therapeutics, Inc.
Via Business Wire
Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy
From Travere Therapeutics, Inc.
Via Business Wire
Travere Therapeutics to Report First Quarter 2025 Financial Results
From Travere Therapeutics, Inc.
Via Business Wire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025
From Travere Therapeutics, Inc.
Via Business Wire
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Participate at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Provides Corporate Update and 2025 Outlook
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Present at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Announces Pricing of Public Offering of Common Stock
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Announces Proposed Public Offering of Common Stock
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Present at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Third Quarter 2024 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Report Third Quarter 2024 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy
Temporary marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT Trial 
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.